Salarius Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLRX research report →
Companywww.salariuspharma.com
Salarius Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
- CEO
- Frederick E. Pierce
- IPO
- 2015
- Employees
- 2
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $4.92M
- P/E
- -0.21
- P/S
- 0.00
- P/B
- 0.69
- EV/EBITDA
- 0.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -395.42%
- ROIC
- -339.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-12,518,480 · -124.52%
- EPS
- $-25.99 · 70.07%
- Op Income
- $-12,613,952
- FCF YoY
- -6.67%
Performance & Tape
- 52W High
- $52.95
- 52W Low
- $0.52
- 50D MA
- $1.12
- 200D MA
- $6.94
- Beta
- 0.32
- Avg Volume
- 3.68M
Get TickerSpark's AI analysis on SLRX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 21, 20 | HANISH ARNOLD C | buy | 4,000 |
| Feb 11, 20 | HANISH ARNOLD C | buy | 4,350 |
Our SLRX Coverage
We haven't published any research on SLRX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLRX Report →